Document mq9x01doDon6DaLkRqo7vZO6B

(gypp) ^Z.ZZG -3 7 ^ P F ('.m}: *i v/ r n p i fir P-1 DuPont Haskell Laboratory for Health and Environmental Sciences Elkton Road, P.O. Box 50 Newark, DE 19714-0050 April 2, 2007 Via Federal Express Document Processing Center (Mail Code 7407M) Room 6428 Attention: 8(e) Coordinator Office of Pollution Prevention and Toxics U.S. Environmental Protection Agency 1201 Constitution Ave., NW Washington, DC 20460 CONTains o CBi Dear 8(e) Coordinator: 8EHQ-0381-0394 Perfluorooctanoate (PFOA) Longitudinal Study Supplement This letter is submitted as a supplement to our May 15, 2006 submission to the above-identified file. In the May 15, 2006 submission, we reported the results of a longitudinal study of serum total cholesterol related to serum PFOA measurements in a group of employees at the DuPont Washington Works, West Virginia plant that participated at least twice in a voluntary serum sampling program at the plant over the last 25 years. Using a mixed effects statistical model with repeated measures for the 454 employees with at least two measurements of serum PFOA, the essential results showed an increase of total cholesterol with increasing serum PFOA of about 1 mg/dl cholesterol per 1 ppm PFOA. A poster presentation was enclosed. Additional data analysis of the results of this study has been completed subsequent to the May 15th submission. From this additional analysis, it was noted that serum PFOA was also negatively associated with total bilirubin (0.008 mg/dl decline per ppm) and positively associated with serum aspartate aminotransferase (0.35 units increase per ppm), but not with other liver enzymes. While DuPont does not believe this information is substantial risk information reportable under TSCA 8(e), DuPont is submitting the information to the TSCA 8(e) office in view of the Agency's continued interest in perfluorinated substances. Sincerely, f- ^'/ A. Michael Kaplan, Ph.B\ Director - Regulatory Affairs and Occupational Health ' . AMK/RWR/RCL: cip (302) 366-5260 89070000199 90 000019 9 E.l. du Pont de Nemours and Company P-2 TSCA 8(e) Submission: 8E H Q -0381-0394 Perfluorooctanoate W ashington W orks Phase III - Longitudinal Study bcc: L J . Fisher M .L. Rees A.V. M alinow ski D. Chase A.M . K aplan R.W. Rickard K.K. M cC ord D.W . Boothe S.E. Sax S.J. D eC arli G.L. K ennedy R.C. Leonard C.J. Sakr Technical File 2